New-Onset Postoperative Atrial Fibrillation Impact on 5-Year Clinical Outcomes and Costs [1]
This month's update on the economical and general aspects of the ROOBY-FS trial. The conclusion (on no impact of de novo post-CABG AF on the incidence of stroke nor the 5 year expenditure ) challenges many hitherto perceptions on this frequent compication of coronary surgery.